Advanced Pharma recalls QUELICIN injection due to lack of sterility assurance
Advanced Pharma recalls QUELICIN (Succinylcholine Chloride) 20 mg/mL injections with potential lack of sterility. Affected lots from May 2017 to July 2017. Consumers should contact the manufacturer for details.
Recall notice
Lack of Assurance of Sterility
Contact the company
What happened, in plain English
Advanced Pharma is recalling QUELICIN injections that may not be sterile. This could lead to infections if used improperly. The recall affects specific lots produced between May and July 2017. Read more at govinfonow.com/recall/41541-advanced-pharma-recalls-quelicin-injection-due-to-lack-of-sterility.
Source Summary by GovInfoNow · govinfonow.com/recall/41541-advanced-pharma-recalls-quelicin-injection-due-to-lack-of-sterility · Updated October 8, 2026 · FDA enforcement record: FDA #D-0953-2017
Cite this page
“Advanced Pharma recalls QUELICIN injection due to lack of sterility assurance.” GovInfoNow, updated October 8, 2026. https://govinfonow.com/recall/41541-advanced-pharma-recalls-quelicin-injection-due-to-lack-of-sterility. Based on FDA recall #D-0953-2017 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0953-2017%22&limit=1).
Why it’s dangerous
The injections may not be sterile, which could cause infections if used in medical procedures. This is a serious concern for patients undergoing surgery or other medical treatments that require injections.
Who’s affected
Healthcare professionals and patients using the recalled QUELICIN injections for medical procedures. Those with the specific lot numbers listed in the recall are most at risk.
How to tell if you have this one
Check the product label for the NDC numbers: 15082-814-67 (5mL vial), 15082-814-79 (7mL vial), or 15082-814-61 (10mL vial). Look for lot numbers from May 2017 to July 2017.
- Brand
Advanced Pharma- Category
Drug
All 4 products in this recall
FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.
- Classification
Class II- Status
Terminated- Distribution
Nationwide with the United States
| Recall number | Product, codes & lots | Quantity |
|---|---|---|
| D-0953-2017 | QUELICIN (Succinylcholine Chloride) Injection, USP 20 mg/mL in a) 5 mL vial (NDC 15082-814-67), b) 7mL vial (NDC 15082-814-79), c) 10mL vial (NDC 15082-814-61), Repackaged by Advanced Pharm, 9265 Kirby Dr., Houston, TX 77054 (877) 794-0404.; Lot #: a) 5/15/17 2305 81467S, BUD 7/29/2017; 5/22/17 1000 81467S, BUD 8/5/2017; 5/30/17 1549 81467S,BUD 8/13/2017. b) 5/24/17 0307 169-81479S, BUD 7/23/2017; 5/18/17 0220 169-81479S, BUD 7/17/2017; 5/16/17 0306 169-81479S, BUD 7/15/2017; 6/5/17 0937 169-81479S, BUD 8/04/2017; 5/16/17 0314 445-81479S, BUD 7/15/2017; 5/16/17 0315 493-81479S, BUD 7/15/2017; c) 5/15/17 2119 81461S, BUD 7/29/2017; 5/22/17 0922 81461S, BUD 8/5/2017; 5/30/17 1533 81461S, BUD 8/13/2017; 6/12/17 1846 81461S, BUD 8/26/2017; 6/5/17 0237 157-81461SB, BUD 8/4/2017. | 2350 units |
| D-0954-2017 | Potassium Phosphate (USP) QS 0.9% Sodium Chloride (USP) 250 mL 20 mmol in NS 250mL Bag, Advanced Pharma, 9265 Kirby Dr., Houston, TX 77054 (877) 794-0404. NDC15082-926-25; Lot #: 5/23/17 1404 299-92625P, BUD: 8/21/2017; 5/26/2017 1250 297-92625P, BUD 8/24/2017. | 72 units |
| D-0955-2017 | Potassium Phosphate (USP) QS 0.9% Sodium Chloride (USP) 250 mL 30 mmol in NS 250mL Bag, Advanced Pharma, 9265 Kirby Dr., Houston, TX 77054 (877) 794-0404. NDC15082-924-25; Lot #: 5/31/17 1416 382-92425P BUD: 8/29/2017 | — |
| D-0956-2017 | Potassium Phosphate (USP) QS 0.9% Sodium Chloride (USP) 250 mL 15 mmol in NS 250mL Bag, Advanced Pharma, 9265 Kirby Dr., Houston, TX 77054 (877) 794-0404. NDC15082-922-25; Lot #: 6/7/17 1446 515-92225P BUD: 9/5/2017; 6/2/17 1100 515-92225P BUD: 8/31/2017; 5/31/17 1415 382-92225P BUD: 8/29/2017. | — |
What to do — step by step
Contact Manufacturer
Reach out to Advanced Pharma at (877) 794-0404 for specific lot information and instructions.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide with the United States” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 5 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0953-2017 (June 22, 2017) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0953-2017 to see it in context.
- Plain-language summary written by qwen3:4b on October 8, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.